



## ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference

November 4, 2020

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 4, 2020-- [ImmunoGen, Inc.](#), (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Virtual London Healthcare Conference. The presentation is scheduled for November 18, 2020 at 12:00pm ET.

A webcast of the presentation will be accessible through the Investors and Media section of the Company's website, [www.immunogen.com](http://www.immunogen.com). Following the live webcast, a replay will be available at the same location.

### ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now."

Learn more about who we are, what we do, and how we do it at [www.immunogen.com](http://www.immunogen.com).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20201104005579/en/>

### INVESTOR RELATIONS AND MEDIA

ImmunoGen

Courtney O'Konek

781-895-0600

[courtney.okonek@immunogen.com](mailto:courtney.okonek@immunogen.com)

OR

FTI Consulting

Robert Stanislaro

212-850-5657

[robert.stanislaro@fticonsulting.com](mailto:robert.stanislaro@fticonsulting.com)

Source: ImmunoGen, Inc.